Tazobactum%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520piperacillin

# Piperacillin/Tazobactam ## Overview Piperacillin/tazobactam is a combination antibiotic consisting of piperacillin, a broad-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Tazobactam protects piperacillin from degradation by many beta-lactamase enzymes, thereby extending its spectrum of activity against susceptible bacteria. ## Primary Indications Piperacillin/tazobactam is indicated for the treatment of moderate to severe infections caused by piperacillin-susceptible organisms, including: * Intra-abdominal infections (complicated) * Pneumonia (nosocomial and community-acquired) * Skin and skin structure infections (complicated) * Gynecologic infections (complicated, e.g., pelvic inflammatory disease) * Bacterial meningitis * Sepsis It is often reserved for more serious infections or when broader coverage is necessary. ## Adult Dosing The typical adult dose is **3.375 grams** (3 grams piperacillin/0.375 grams tazobactam) or **4.5 grams** (4 grams piperacillin/0.5 grams tazobactam) intravenously every 6 or 8 hours. * **Dosage Frequency:** Dosing every 6 hours is often preferred for severe infections or when targeting organisms with longer post-antibiotic effects. * **Duration of Therapy:** Varies based on infection severity and patient response, typically 7 to 14 days. * **Maximum Dose:** Not explicitly defined, but individual component limits are generally considered. ## Pediatric Dosing * **Infants and Children (≥ 2 months of age):** Dosing is based on piperacillin weight. * **3.375 grams IV every 6 hours:** 25 mg piperacillin/3.125 mg tazobactam per kg per dose. * **4.5 grams IV every 6 hours:** 33.75 mg piperacillin/4.125 mg tazobactam per kg per dose. * **Maximum Dose:** Limited by total daily dose of piperacillin (e.g., 24 grams/day for a typical pediatric indication) and tazobactam. ## Dose Adjustments * **Renal Impairment:** * CrCl > 40 mL/min: No adjustment needed. * CrCl 20-40 mL/min: Administer usual dose every 8 hours. * CrCl < 20 mL/min: Administer usual dose every 12 hours. * Hemodialysis: Administer usual dose every 12 hours and supplement with one additional dose during hemodialysis. * **Hepatic Impairment:** No specific dose adjustments are typically recommended, but caution is advised. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, other penicillins, or beta-lactamase inhibitors. * History of a severe allergic reaction (e.g., anaphylaxis) to any beta-lactam antibiotic. ## Adverse Effects * **Common:** Diarrhea, rash, nausea, vomiting, headache, insomnia. * **Serious:** *Clostridioides difficile*-associated diarrhea, hypersensitivity reactions (including anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, seizures, interstitial nephritis, hepatic dysfunction, hematologic changes (neutropenia, thrombocytopenia). ## Key Drug Interactions * **Probenecid:** May increase and prolong piperacillin/tazobactam serum concentrations. * **Neuromuscular Blocking Agents (e.g., vecuronium):** Piperacillin may prolong the action of vecuronium. * **Warfarin:** Piperacillin may decrease serum concentrations of warfarin, potentially reducing INR. Monitor INR closely. * **Methotrexate:** Piperacillin may reduce methotrexate clearance. Monitor methotrexate levels. ## Monitoring * **Renal function:** Especially in patients with pre-existing renal impairment or those receiving nephrotoxic agents. * **Liver function tests:** Periodically. * **Hematologic parameters:** Complete blood count, including platelet counts, especially with prolonged therapy. * **Signs and symptoms of infection:** Clinical response to therapy. * **Signs of *Clostridioides difficile*-associated diarrhea.** * **Electrolytes:** Monitor for potential hypernatremia, especially with prolonged infusions. ## Clinical Pearls * The choice of piperacillin/tazobactam should be guided by susceptibility testing and institutional antibiogram data. * Ensure adequate hydration to prevent crystalluria. * Administer intravenously over at least 30 minutes to minimize infusion-related reactions. Rapid infusion can increase the risk of seizures. * For patients with cystic fibrosis, higher doses may be required, and specific protocols should be followed. *** *This information is intended for healthcare professionals. Always verify current prescribing information with the official product labeling and consult with a qualified healthcare provider for any medical advice or treatment decisions.*